ANALYSIS OF THE POSSIBILITY OF USING DALARGIN IN COMPREHENSIVE TREATMENT OF COVID-19-Reference-Cited by-同舟云学术

ANALYSIS OF THE POSSIBILITY OF USING DALARGIN IN COMPREHENSIVE TREATMENT OF COVID-19

Published:2020-07-16 Issue: Volume: Page:
ISSN:2663-4139
Container-title:ΛΌГOΣ МИСТЕЦТВО НАУКОВОЇ ДУМКИ
language:uk
Short-container-title:logos

Author:

Martynov Yu.¹,Kukovska I.¹

Affiliation:

1. Bukovinian State Medical University

Abstract

The article considers the biochemical properties and mechanisms of action of dalargin - an analogue of leu-enkephalin on the human body. The relationship between the properties of the medicine and the pathogenetic mechanisms of COVID-19 disease and its complications has been established. Conclusions are made regarding the feasibility of research to study the possibility of using the medicine in combination therapy in the treatment of coronavirus disease.

Publisher

European Scientific Platform Publishing

Reference39 articles.

1. Животова, Е. Ю., Лебедько, О. А., & Тимошин, С. С. (2012). Влияние структурных аналогов лей-энкефалина на процессы синтеза ДНК и свободнорадикальное окисление в слизистой оболочке желудка белых крыс. Дальневосточный медицинский журнал, (1), 109.

2. Николаев А.В. & Слепушкин В.Д. (2000). Отечественный препарат даларгин и его использование в онкологии (Серия: “Будьте здоровы”), с. 14–16.

3. An Open Randomized Study of Dalargin Effectiveness in Patients with Severe and Critical Manifestations of SARS-COVID-19. Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT04346693.

4. Насонов, Е.Л. (2020). Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология, 58(2), 123-132.

5. Klok, F.A., Kruip, M., van der Meer, N., Arbous, M.S., Gommers, D., Kant, K.M., Kaptein, F., van Paassen, J., Stals, M., Huisman, M.V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research, 191, 145–147. https://doi.org/10.1016/j.thromres.2020.04.013